An assessment of platelet parameters in different ethnic groups with hypertension subtypes and associated risk factors in Xinjiang, China. (18th August 2018)

• Record Type: Journal Article
• Authors: Abudesimu, Asiya; Liu, Fen; Siti, Dilixiati; Adi, Dilare; Fu, Zhenyan; Ma, Xiang; Xie, Xiang; Yang, Yining; Li, Xiaomei; Ma, Yitong
• Is Part Of: Clinical and experimental hypertension. Volume 40:Number 6(2018)
• Page Start: 574
• Page End: 581
• Publication Date: 2018-08-18
• Subjects: Blood platelets -- thrombosis -- hypertension -- ethnic groups -- cross-sectional study; Hypertension -- Chemotherapy -- Periodicals; Hypotensive agents -- Periodicals; 616.132
• DOI: 10.1080/10641963.2017.1411494
• Languages: English
• ISSNs: 1064-1963

Abstract

ABSTRACT: The goal of this study was to investigate platelet parameters in populations with hypertension subtypes among the Han, Uygur, and Kazakh ethnic groups and their associated risk factors in Xinjiang, northwestern China. In total, 9816 adult participants were recruited from a multiethnic, cross-sectional cardiovascular risk survey. Our results indicated that the platelet counts in Han, Uygur, and Kazakh participants with isolated systolic hypertension (ISH), isolated diastolic hypertension (IDH), and systolic diastolic hypertension (SDH) varied significantly ( P < 0.001). Additionally, the mean platelet volume (MPV) in Han, Uygur, and Kazakh participants with ISH was significantly different ( P < 0.05). Furthermore, the individual platelet parameters had different associated risk factors. For example, the risk factors for platelet counts were Uygur ethnicity, Kazakh ethnicity, drinking, ISH, diabetes, and high triglycerides (TGs). The risk factors for MPV were Uygur ethnicity, smoking, overweight, obesity, ISH, IDH, diabetes, and high TGs. Gender was a risk factor for abnormal plateletcrit (PCT) values. Only a low high-density lipoprotein cholesterol level was found to be a risk factor for platelet distribution width (PDW). We suggest that more attention should be paid to platelet parameters and the associated risk factors to reinforce the effect of antiplatelet therapy and to provide a clinical basis for preventing the occurrence of thrombosis complications and cerebro- and cardiovascular diseases effectively.